Mydriacyl

TROPICAMIDE OPHTHALMIC HUMAN PRESCRIPTION DRUG

Mydriacyl is an FDA drug label for the active ingredient TROPICAMIDE manufactured by Alcon Laboratories, Inc. administered by OPHTHALMIC. This page reproduces the FDA-approved indications and usage, dosage, contraindications, warnings, and adverse reactions exactly as published in the drug label. Data source: openFDA (U.S. FDA), label effective 20230215.

Generic name
TROPICAMIDE
Manufacturer
Alcon Laboratories, Inc.
Product type
HUMAN PRESCRIPTION DRUG
Route
OPHTHALMIC
Dosage form
N/A
NDC
0998-0355
Application
ANDA084306
Label effective
20230215

Indications & Usage

INDICATIONS AND USAGE For mydriasis and cycloplegia for diagnostic procedures.

Dosage & Administration

DOSAGE AND ADMINISTRATION For refraction, instill one or two drops of 1% solution in the eye(s), repeated in five minutes. If patient is not seen within 20 to 30 minutes, an additional drop may be instilled to prolong mydriatic effect. For examination of fundus, instill one or two drops of 0.5% solution 15 or 20 minutes prior to examination. Individuals with heavily pigmented irides may require higher strength or more doses. Mydriasis will reverse spontaneously with time, typically in 4 to 8 hours. However, in some cases, complete recovery may take up to 24 hours.

Contraindications

CONTRAINDICATIONS Contraindicated in persons showing hypersensitivity to any component of this preparation.

Warnings

WARNINGS FOR TOPICAL OPHTHALMIC USE ONLY. NOT FOR INJECTION. This preparation may cause CNS disturbances which may be dangerous in pediatric patients. The possibility of psychotic reactions and behavioral disturbances due to hypersensitivity to anticholinergic drugs should be considered. Mydriatics may produce a transient elevation of intraocular pressure. Remove contact lenses before using.

Adverse Reactions

ADVERSE REACTIONS Ocular: Transient stinging, blurred vision, photophobia and superficial punctuate keratitis have been reported with the use of tropicamide. Increased intraocular pressure has been reported following the use of mydriatics. Non-Ocular: Dryness of the mouth, tachycardia, headache, allergic reactions, nausea, vomiting, pallor, central nervous system disturbances and muscle rigidity have been reported with the use of tropicamide. Psychotic reactions, behavioral disturbances, and vasomotor or cardiorespiratory collapse in children have been reported with the use of anticholinergic drugs.

More products with the same ingredient

TROPICAMIDE

Tropicamide

Sandoz Inc View label

Tropicamide

Bausch & Lomb Incorporated View label

Tropicamide

Sandoz Inc View label